Skip to Main Content

Gilead’s research and development chief is stepping down after nearly three decades at the company, concluding a run in which he steered the development of pioneering blockbuster therapies for HIV and hepatitis C but more recently became the target of Wall Street ire amid Gilead’s struggles to find a third act.

Norbert Bischofberger will leave his post at the end of April but will stay with the company through July, Gilead (GILD) announced on Monday. The company did not give a reason for his departure, but the move offers Gilead a chance to freshen its uppermost ranks without shaking up its strategy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!